Additionally, compared with standard chemotherapy, EGFR-TKIs displayed higher safety, better tolerability, and patients had improved quality of life when used as the first-line treatment for patients with advanced EGFR-positive NSCLC in previous studies [6–8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.